Calico Life Sciences LLC
Privately held: no public share price · United States
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | EIF2B (eIF2B activator) | Indication not yet linked | |
| Phase 1 | PTPN2/PTPN1Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
November 2027 (1)
Est. primary completion 2027-11 · NCT05757141 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
6 January 2025Topline resultFosigotifatorHEALEY ALS Platform Trial Regimen F (NCT05740813) Phase 2/3 missed its primary endpoint
Calico Life Sciences LLC (Calico) · Source ↗
Financial reports
No financial reports recorded.